Why EnteroMedics (ETRM) Stock Is Surging Today

NEW YORK (TheStreet) -- EnteroMedics  (ETRM) surged Wednesday after the medical device developer announced a Food and Drug Administration panel had voted positively on VBLOC vagal blocking therapy for obesity treatment.

The FDA's Advisory Gastroenterology and Urology Devices Panel, or GUDP, voted 8 to 1 in favor that the device is safe when used as designed and 4 to 5 "against" on the subject of reasonable assurance of efficacy. The final vote was 6 to 2 in favor, with one abstention, of VBLOC's benefits outweighing the risks.

The FDA does not have to follow the GUDP's recommendation, but it will factor it in when reviewing the Maestro System Premarket Approval (PMA). EnteroMedics expects a decision on PMA approval later this year.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 15.78% to $1.76 at 10:21 a.m. Nearly 11 million shares had changed hands, which beat the average volume of 1,329,210. 

ETRM Price Chart

ETRM Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing